High Blood Pressure & Cardiovascular Prevention

, Volume 22, Issue 2, pp 99–102

Are the Antagonists of the Renin–Angiotensin System Also Anticancer Agents?

Review Article

DOI: 10.1007/s40292-014-0059-y

Cite this article as:
Lonati, C. & Morganti, A. High Blood Press Cardiovasc Prev (2015) 22: 99. doi:10.1007/s40292-014-0059-y


The antagonists of the renin–angiotensin system (RAS) have gained increasing popularity in the last two decades due to their indisputable efficacy in a number of cardiovascular disorders, coupled with an unsurpassed tolerability. However some years ago a partial and non-predefined meta-analysis raised the possibility that angiotensin receptor antagonists in particular may increase the incidence of cancer. This observation, although not confirmed by subsequent, larger analyses, caused a remarkable and understandable concern even outside the medical community. Herein we will summarize the available evidence pro and con the hypothesis of a carcinogenetic activity of RAS antagonists coming to the conclusion that these drugs may actually exert an anticancer action.


Renin-angiotensin systemRenin-angiotensin system antagonistsCancer

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Division of Internal Medicine and Hypertension Center, Department of Clinical Sciences and Community Health, San Giuseppe HospitalUniversity of MilanMilanItaly
  2. 2.Department of Internal MedicineOspedale San GiuseppeMilanItaly